MiR-193a-3p: A pan-repressor of H2S synthesizing enzymes regulates tumorigenesis and immunosurveillance in breast cancer

被引：1
|
作者：
Dawoud, A. [1 ]
Youness, R. A. [2 ]
Nafea, H. M. [1 ]
Bourquin, C. [3 ]
Szabo, C. [4 ]
Abdel-Kader, R. M. [5 ]
Gad, M. [1 ]
机构：
[1] GUC German Univ Cairo, Biochem Dept, New Cairo, Egypt
[2] GUC German Univ Cairo, Pharmaceut Biol Dept, New Cairo, Egypt
[3] UNIGE Univ Geneve Ctr Med Univ CMU, Dept Anaesthesiol Pharmacol Intens Care & Emergen, Geneva, Switzerland
[4] Univ Fribourg, Pharmacol, Fribourg, Switzerland
[5] GUC German Univ Cairo, Pharmacol & Toxicol Dept, New Cairo, Egypt
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
基金：
瑞士国家科学基金会;
关键词：
D O I：
10.1016/j.annonc.2023.09.1308
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2280P
引用
收藏
页码：S1169 / S1169
页数：1
相关论文
共 45 条
  • [41] Dietary Methionine Restriction Upregulates Endogenous H2S via miR-328-3p: A Potential Mechanism to Improve Liver Protein Metabolism Efficiency in a Mouse Model of High-fat-diet-induced Obesity
    Wu, Guoqing
    Wang, Yanan
    Yang, Yuhui
    Shi, Yonghui
    Sun, Jin
    Xu, Yunchong
    Luo, Tingyu
    Le, Guowei
    MOLECULAR NUTRITION & FOOD RESEARCH, 2019, 63 (05)
  • [42] Ginsenoside 20(S)-Rg3 Prevents PKM2-Targeting miR-324-5p from H19 Sponging to Antagonize the Warburg Effect in Ovarian Cancer Cells
    Zheng, Xia
    Zhou, Yuanyuan
    Chen, Wei
    Chen, Lihong
    Lu, Jiaojiao
    He, Fang
    Li, Xu
    Zhao, Le
    CELLULAR PHYSIOLOGY AND BIOCHEMISTRY, 2018, 51 (03) : 1340 - 1353
  • [43] RETRACTED: Identification of lncRNA TRPM2-AS/miR-140-3p/PYCR1 axis's proliferates and anti-apoptotic effect on breast cancer using co-expression network analysis (Retracted Article)
    Sun, Tong
    Song, Yan
    Yu, Hong
    Luo, Xiao
    CANCER BIOLOGY & THERAPY, 2019, 20 (06) : 760 - 773
  • [44] RETRACTION: Identification of lncRNA TRPM2-AS/miR-140-3p/PYCR1 axis's proliferates and anti-apoptotic effect on breast cancer using co-expression network analysis (Retraction of Vol 20, Pg 760, 2019)
    Sun, T.
    Song, Y.
    Yu, H.
    Luo, X.
    CANCER BIOLOGY & THERAPY, 2020, 21 (09) : 871 - 871
  • [45] CALGB 9840: Phase III study of weekly (W) paclitaxel (P) via 1-hour(h) infusion versus standard (S) 3h infusion every third week in the treatment of metastatic breast cancer (MBC), with trastuzumab (T) for HER2 positive MBC and randomized for T in HER2 normal MBC
    Seidman, AD
    Berry, D
    Cirrincione, C
    Harris, L
    Dressler, L
    Muss, H
    Norton, L
    Winer, E
    Hudis, C
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 6S - 6S
12345